Stock News

EPS for VistaGen Therapeutics, Inc. (VTGN) Expected At $-0.28; 2 Analysts Are Bullish ANGLE plc (LON:AGL) Last Week

ANGLE plc (LON:AGL) Logo

Among 2 analysts covering Angle PLC (LON:AGL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Angle PLC had 31 analyst reports since July 24, 2015 according to SRatingsIntel. The company was maintained on Friday, January 27 by Beaufort Securities. The firm has “Speculative Buy” rating given on Wednesday, July 20 by Beaufort Securities. The rating was maintained by Beaufort Securities on Friday, July 24 with “Speculative Buy”. The stock of ANGLE plc (LON:AGL) earned “Corporate” rating by FinnCap on Monday, October 23. The firm has “Speculative Buy” rating given on Friday, June 16 by Beaufort Securities. The stock of ANGLE plc (LON:AGL) earned “Speculative Buy” rating by Beaufort Securities on Monday, November 7. The stock of ANGLE plc (LON:AGL) has “Speculative Buy” rating given on Tuesday, April 4 by Beaufort Securities. On Tuesday, April 19 the stock rating was maintained by Beaufort Securities with “Speculative Buy”. The rating was maintained by FinnCap on Monday, October 9 with “Corporate”. Beaufort Securities maintained ANGLE plc (LON:AGL) on Thursday, July 28 with “Speculative Buy” rating. See ANGLE plc (LON:AGL) latest ratings:

19/04/2018 Broker: FinnCap Rating: Corporate New Target: GBX 108.00 Maintain
05/04/2018 Broker: FinnCap Rating: Corporate Old Target: GBX 108.00 Maintain
26/03/2018 Broker: FinnCap Rating: Corporate Old Target: GBX 108.00 New Target: GBX 108.00 Maintain
12/02/2018 Broker: FinnCap Rating: Corporate Old Target: GBX 108.00 New Target: GBX 108.00 Maintain
31/01/2018 Broker: FinnCap Rating: Corporate Old Target: GBX 108.00 New Target: GBX 108.00 Maintain
08/01/2018 Broker: FinnCap Rating: Corporate Old Target: GBX 108.00 New Target: GBX 108.00 Maintain

Analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to report $-0.28 EPS on July, 5.They anticipate $0.04 EPS change or 12.50% from last quarter’s $-0.32 EPS. After having $-0.24 EPS previously, VistaGen Therapeutics, Inc.’s analysts see 16.67% EPS growth. The stock decreased 0.70% or $0.01 during the last trading session, reaching $1.41. About 401,383 shares traded. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has declined 19.67% since June 13, 2017 and is downtrending. It has underperformed by 32.24% the S&P500. Some Historical VTGN News: ; 23/05/2018 – VistaGen Therapeutics Receives Notice of Allowance of U.S. Patent for Treatment of Osteoarthritis and Joint Injuries with Stem; 10/04/2018 – VISTAGEN THERAPEUTICS INC – RECEIVES EUROPEAN PATENT REGARDING METHODS OF PRODUCTION FOR AV-101; 10/04/2018 – VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101; 05/04/2018 – VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder; 23/05/2018 – VistaGen Therapeutics Receives Notice of Allowance of U.S. Patent for Treatment of Osteoarthritis and Joint Injuries with Stem Cell-Derived Chondrocytes and Cartilage; 05/04/2018 – VISTAGEN THERAPEUTICS INC – TOP-LINE RESULTS FROM ELEVATE ARE EXPECTED IN FIRST HALF OF 2019; 02/05/2018 – VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent regarding Methods of Production for AV-101; 07/03/2018 VistaGen Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering Treatment of Depression with AV-101; 19/03/2018 – VistaGen Therapeutics Receives a Notice of Allowance for Another Key U.S. Patent Covering Oral Formulations of AV-101

The stock increased 0.54% or GBX 0.3 during the last trading session, reaching GBX 55.6. About 3,400 shares traded. ANGLE plc (LON:AGL) has 0.00% since June 13, 2017 and is . It has underperformed by 12.57% the S&P500.

ANGLE plc, a medical diagnostic company, provides cancer diagnostics and foetal health products. The company has market cap of 65.04 million GBP. The Company’s lead product is Parsortix cell separation system, which captures very rare circulating tumor cells in cancer patient blood. It currently has negative earnings. The resulting liquid biopsy enables the investigation of mutations in the patientÂ’s cancer for personalized cancer care.

Another recent and important VistaGen Therapeutics, Inc. (NASDAQ:VTGN) news was published by Seekingalpha.com which published an article titled: “Oppenheimer bullish on VistaGen; shares up 62%” on May 25, 2018.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system disorders. The company has market cap of $32.29 million. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It currently has negative earnings. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells.

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *